Business Wire

Vecima Acquires Falcon V Systems, Provider of Innovative Software Orchestration Platform for Cable, Fiber, and Mobile Access Networks

Share

Combination of Vecima’s Entra Cloud™ and Falcon’s Principal Core and Test Suite will help operators accelerate and simplify cable, fiber, and mobile access network and service flow convergence, using automated software tools and testing Charter Communications will be the initial customer, signing a multi-year deal to deploy both the Principal Core and Test Suite Falcon V Systems’ open, interoperable platform supports multiple vendors’ vCMTS platforms, including Vecima’s Entra® vCMTS & Entra® vPON Manager

Vecima Networks, Inc. (TSX: VCM) today announced that, through its subsidiary Vecima Technology B.V., it has acquired Falcon V Systems, a Poland-based provider of vendor-agnostic, virtualized software solutions and services for Broadband Service Providers worldwide.

Vecima has acquired all outstanding Falcon V Systems shares, as well as the company’s technology, intellectual property, and talent. With the close of the acquisition today, Vecima will onboard a significant portion of the Falcon V team which will be integrated into Vecima’s Video & Broadband Solutions business, comprising its market-leading Entra broadband access portfolios and talent.

Falcon V Systems’ key products will be integrated into Vecima’s Entra Cloud™ portfolio of open, interoperable, cloud-native applications that help cable operators transform their networks for next-generation broadband access:

  • Falcon V Systems’ Principal Core manages across multiple cable, fiber, and mobile cores, allowing a multivendor environment, with seamless integration across the OSS/BSS ecosystem — a convergence of services not possible previously.

  • The Test Suite is a comprehensive set of tools, focused on helping Broadband Service Providers accelerate deployments and feature enhancements, through an automated, end-to-end test environment.

“I’m incredibly proud of what the Falcon V team has accomplished, and I extend my sincerest thanks to our talented Falcon team, our partners, and our customers,” said Ulf Andersson, CEO of Falcon V Systems. “Vecima will take our work forward and bring it to market on a global scale, unlocking the potential of the Falcon V technology and team.”

“Our work over the last several years with Falcon V Systems has been a critical component in our long-term access architecture strategy, enabling us to simplify and enhance the subscriber experience,” said Justin Colwell, Executive Vice President, Connectivity Technology, Charter Communications. “We plan to deploy the Principal Core, which will be a component of Vecima’s vCMTS solution, along with the Test Suite, and look forward to working closely with Vecima to lead wider adoption of the Entra Cloud platform across the industry.”

“Flexibility and interoperability are the cornerstone of Vecima’s unique approach to access networks and the hallmark of Falcon V Systems’ automation and orchestration software,” said Clay McCreery, Chief Operating Officer at Vecima. “With this acquisition, Vecima expands its research and development footprint into Europe with an expert team of DAA technologists in Poland. Falcon V Systems will be able to take advantage of Vecima’s global scale, existing vCMTS and PON platforms, and extensive customer relationships.”

“Vecima’s mission is to empower service providers globally with the transformative solutions that usher in the new multi-gigabit connectivity era to come,” said Sumit Kumar, Vecima President and Chief Executive Officer. “We are embarking on a new phase of growth, and by adding the Falcon V Systems team and technology to our expansive industry-leading broadband access portfolio, we broaden, once more, our ability to meet the evolving network convergence needs of Broadband Service Provider customers worldwide. With the Falcon team & Charter’s long-term partnership, this acquisition further deepens Vecima’s leadership in the Broadband Service Provider segment.”

About Falcon V Systems

Falcon V Systems is an independent challenger that delivers a cost-effective, scalable, and non-proprietary open DAA solution for Broadband Service Providers based on Software Defined Networking (SDN) and Network Functions Virtualization (NFV). This non-monolithic, agile architecture will enable more efficient use of network assets, data centers, and cloud assets. Thanks to open interfaces, the solution evolves along with the growth of needs and supports the cooperation between operators and other vendors.

About Vecima Networks

Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at vecima.com.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words “believes”, “may”, “plans”, “will”, “anticipates”, “intends”, “could”, “estimates”, “expects”, “forecasts”, “projects” and similar expressions, and the negative of such expressions.

Forward-looking information in this news release includes, but is not limited to, any statements respecting: Vecima will onboard a significant portion of the Falcon V team which will be integrated into Vecima’s Video & Broadband Solutions business; closing of the transaction will allow Vecima to expand its research and development footprint into Europe; Falcon V Systems’ key products will be integrated into Vecima’s Entra Cloud™ portfolio; Charter Communications’ plans to deploy the Principal Core and Test Suite.

The forward-looking statements are based on the current expectations of the management of Vecima and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated.

A more complete discussion of the risks and uncertainties facing Vecima is generally disclosed under the heading “Risk Factors” in the Company’s Annual Information Form dated September 19, 2024, as well as the Company’s continuous disclosure filings with Canadian securities regulatory authorities available at www.sedarplus.ca. All forward-looking information herein is qualified in its entirety by this cautionary statement, and Vecima disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events, or developments, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241010671688/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye